Abstract: Introduction: Inhibition of self-reactive T cells through induction of antigen-specific immune tolerance holds the promise of effective treatment of autoimmune pathology with few side effects and preservation of normal immune functions. In multiple sclerosis (MS) several approaches have been tested already in clinical trials or are currently ongoing with the aim to inhibit myelin-reactive immune responses. Areas covered: This article provides an overview of the recent and ongoing strategies to inhibit specific immune responses in MS, including different applications of myelin peptide-based approaches, T-cell vaccination, DNA vaccination and antigen-coupled cells. Expert opinion: Despite difficulties in translation of antigen-specific therapies in MS, novel approaches have the potential to effectively induce immune tolerance and ameliorate the disease. To improve efficacy of treatments, future trials should include patients in the early phases of the disease, when the autoimmune response is predominant and immune reactivity still focused. The target antigens are not fully defined yet, and robust immunomonitoring assays should developed to provide mechanistic proof of concept in parallel to showing efficacy with respect to inhibiting inflammatory disease activity in the central nervous system (CNS). 
Introduction:
Targeted inhibition of antigen-specific T cells can be viewed as the most direct and specific means of correcting pathogenic immune responsiveness, which underlies many organ-specific autoimmune diseases [1] [2] [3] . The main goal of such approaches is to stop or reverse an autoreactive T cell response by specifically inducing immune tolerance to the target selfantigens. Compared to unspecfic immunomodulatory or immunsuppressive interventions, antigen-specific therapies have the advantage that they should in principle only affects the pathogenic immune response without altering physiological immune responsiveness.
Extensive pre-clinical research on basic mechanisms of autoimmunity and immune tolerance facilitated translation of several therapeutic approaches in patients with autoimmune disease in general and multiple sclerosis (MS) in particular. Although the etiology of MS is as yet not fully understood, all current therapeutic approaches are based on the concept that the disease is driven by an immune response directed against self-antigens in the central nervous system (CNS) [4] . Based on extensive research in the animal model of MS, experimental autoimmune encephalomyelitis (EAE), and the fact that the HLA-DR15 haplotype confers most of the genetic risk to develop MS, it has long been considered the prototype of a CD4+
T cell-mediated disease [4] . However, there is increasing evidence for a role of several other compartments of the immune system including CD8+ T cells, B cells/antibodies, and cytokines/chemokines. Despite these data, there is little doubt that CD4+ T cells play a central role in orchestrating the pathogenic immune response in MS patients, and they are consequently viewed as important target for therapeutic intervention. Also, while the armamentarium of approved therapies for MS, which includes small molecule drugs, monoclonal antibodies and other biologics (peptidic compounds, interferon-beta) has grown substantially in the last two decades, and these therapies offer moderate to high efficacy, all inhibit the immune response in an unspecific manner,require long-termapplication and are associated with sometimes serious-to life-threatening risks. Targeting the pathogenic autoreactive T cell response by direct intervention offers the opportunity to treat the disease with few side effects and has the potential for long-lasting clinical benefit, since it aims to correct the causes of autoimmune diseases at their roots. Approaches that aim at a specific inhibition of autoreactive T cells are subject of this review.
Principles of antigen-specific / T cell mediated therapies
Reactivity against self is inherent to the function of the adaptive arms of the immune system, i.e. antibodies and T cells, and under physiological conditions multiple safeguards avoid that high affinity and pathogenic autoantibodies or autoreactive T cells develop. Hence, pathogenic autoimmunity is avoided at several developmental steps, first in the thymus (central tolerance), where thymocytes are eliminated by clonal deletion if they recognize self-HLA together with self-peptides with high avidity [5] . It is important to note that despite this first checkpoint, where high avidity self-reactive T cells are eliminated, those that are positively selected and constitute the peripheral T cell repertoire have all been selected on self-HLA/self-peptide complexes, which means that they all are in principle autoreactive.
Therefore, further safeguard mechanisms are required to maintain immunologic tolerance at the level of peripheral immune activation. All therapeutic strategies aiming to induce antigenspecific tolerance operate at the level of peripheral tolerance, since it is not possible to influence central tolerance mechanisms. Antigen-presentation and activation of autoreactive effector T cells are the main processes, which are targeted by tolerization approaches.
The most essential process in the activation of an effector T cell is the formation of the immune synapse between the T cell and an APC (Figure) . This highly specific interaction requires formation of the trimolecular complex (signal 1), engaging the HLA class II molecule of the APC, the antigenic peptide bound to the HLA class II molecule and the T cell receptor (TCR). Formation of a stable immune synapse is further dependent on the interaction of different molecules between the APC and the T cell, which can have both stimulatory or inhibitory effects (signal 2). Peripheral tolerance can act at different levels in the formation of the immune synapse (Figure) . In the absence of costimulatory signals, i.e. signal 2, upon engagement of the trimolecular complex a T cells is rendered unresponsive to antigen stimulation, a state that is referred to as anergy [6] . Anergy can persist even if the antigen is later presented by a fully competent APC, however it is in principle transient and reversible and can be overcome by interleukin-2 [7, 8] . Engagement of a negative second signal pathway between the APC and the T cell (eg CTLA4/CD80 or CD86, PD1/PD1L) leads to clonal deletion through apoptosis of T cells [9] [10] [11] . Overactivation of the TCR in a pre-activated T cell might lead to apoptosis of the T cell by activation induced cell death (AICD), via the interaction of FasLigand with Fas [12] [13] [14] .
Besides the above direct means of functionally silencing or eliminating an autoreactive T cell, autoreactivity can also actively be suppressed by indirect mechanisms that involve regulatory T cells (Tregs) [15] [16] [17] , and the latter cells have also been employed for tolerization approaches [18] . Neither Tregs nor any of the other abovementioned mechanisms usually maintains peripheral tolerance alone. Instead it is more likely that these act in concert and probably need to be broken at several levels before overt autoimmune diseases develop. Also, while mechanisms like anergy, insufficient-or too strong activation are supposedly more important for an early reduction in pathogenic T cell responses, the induction of Treg has the potential to lead to a long-term and stable inhibition of pathogenic, autoreactive T cell responses [19] . Furthermore, alterations in the cytokine milieu with the aim to skew the effector subsets from a proinflammatory (ie. TH1, TH17) to an anti-inflammatory phenotype (TH2, Tr1), a process referred to as immune deviation, can lead to the induction and maintenance of immune tolerance [20] .
While the basic mechanisms of T cell tolerance involve the interaction with the trimolecular complex or induction of regulatory cell and/or cytokine responses the approaches used to achieve this inhibition of T cells differ in their methods as well as the route of administration (Figure) . Many approaches focused on the specific self-peptide as the central structure of the trimolecular complex responsible for a stable interaction between the HLA and the TCR.
When using synthetic peptides different routes of administration have been shown to induce tolerance. In MS, clinical trials were performed with mucosal, intravenous, sub-, intra-or epicutaneous application of peptides, which derived mostly from peptides of myelin basic protein (MBP) but also of other myelin proteins including myelin oligodendrocyte protein (MOG) and proteolipid protein (PLP) ( Table) . A different strategy relied on synthetic peptides, which had been modified in their interacting regions, i.e. altered peptide ligands (Table) . As opposed to myelin peptides the TCR of a pathogenic myelin-specific T cell population can also be used as target structure, either through administration of peptides corresponding to regions of the complementarity determining region of TCRs or injection of attenuated pathogenic myelin-specific T cells (Table) . Both approaches have been tested in clinical trials in MS patients. Finally intravenous infusion of autologous, antigen-coupled cells is a novel approach currently tested for treatment of MS.
Myelin peptide-based approaches to induce tolerance in MS

Mucosal administration of myelin peptides
Induction of tolerance via oral or mucosal administration of peptides is an appealing approach not only because of advantages for patients with regard to applicability but also with regard to its favorable safety profile in preclinical studies [20] . The immunologic mechanisms of oral tolerance involve clonal anergy or deletion when given at a high dose whereas low dose treatment leads to bystander suppression through the release of suppressive cytokines, such as TGF-ß, IL-4 or IL-10 by regulatory T cells [21] . However, despite promising results in preclinical models, both clinical phase I/II trials as well as a large phase III placebo-controlled trial with oral bovine MBP in 515 MS patients failed [22] . Nevertheless, discussion is still ongoing as to whether dosage or formulation of myelin might have influenced efficacy of the treatment and whether an unusually strong placebo effect in the phase III trial has contributed to the negative outcome of the phase III trial. Moreover, histological analyses from skin biopsies at the site of application and samples from draining local lymph nodes revealed activated dendritic Langerhans cells in the skin and a population of granular dendritic cells in local lymph nodes. In summary, this is a promising approach given the easy applicability of the peptide product. Beneficial clinical effects are underscored by mechanistic studies suggesting induction of immune tolerance. subcutaneously, and c) the unusual HLA-class II composition of the small group of patients with very few expressing HLA-DR15, probably all contributed.
Altered peptide ligands
DNA vaccination
The principle of this tolerization strategy is a heterotopic expression of a specific target antigen with the aim to induce antigen-specific tolerance. A DNA vaccine of whole human MBP protein (BHT-3009, Bayhill Therapeutics) was chosen as target antigen [37, 38] . In practice, a plasmid encoding the auto-antigen is injected intramuscularly, which leads to low- 
T cell receptor vaccination
Antigen-coupled cell tolerance
A tolerization strategy, which looks very promising based on extensive experience in various animal models [8,19,55- 
Summary
Several approaches aiming at antigen specific tolerance in MS have already been successfully 
Expert Opinion
Despite many successes in animal models of MS and also other autoimmune diseases the translation of antigen-specific therapies to MS patients or in general to organ-specific autoimmune diseases resulted in several difficulties including lack of efficacy, or even disease exacerbation and hypersensitivity reactions. In our opinion, the pitfalls do, however, not only lie in clinical outcomes of safety and efficacy but also various immunological and conceptual aspects.
Target antigens
Over the last decades many groups have studied the immune response in MS patients [4] . In summary, although a single target antigen could not be identified in MS the evidence for myelin proteins as importat targets of the autoimmune response is fairly robust across different studies in several cohorts of MS patients. Given the possibility that the target antigens differ between patients and may even change throughout the disease, because of epitope spreading, tolerization strategies, which offer the possibility t target various antigens at the same time are more likely to be successful in MS.
Patient population and trial design
Many trials, which tested new antigen-specific therapies in MS, included progressive patients with long-standing disease course, However, at later stages of the disease, antigen-specific autoimmune inflammation might be less relevant than during the earlier stages of the disease, and patients in the progressive phase of the disease are usually not amenable to any of the currently available treatments. Hence, trying to provide proof-of-concept and show efficacy in the progressive stage is difficult if not impossible, and several of the above approaches were unfortunately mainly tested in progressive patients. Further, as already mentioned above it is likely that the specific immune response spreads to several antigens during the disease.
Consequently, in future therapeutic trials aiming at antigen-specific tolerance it will be crucial to start treatment early in RR-MS patients, ideally within the first five years from onset of the disease. Patients should be tested for their reactivity before inclusion in the trial, and this should be a pre-requisite for treatment to follow its immunological effects. Clinical trials should be accompanied by appropriate mechanistic studies to measure the effect of the treatment on the immune system, not only as a relevant safety parameter but also as a measure of biological effect, i.e. if antigen-specific tolerance has indeed been induced. The proof-ofconcept that induction of tolerance against specific antigens is able to halt the disease will only be possible by efficient combination of immunologic and clinical/MRI based outcome parameters. For several tolerization strategies we further expect that they will at least in part depend on the specific HLA-class II background of individuals. Thus, the HLA-class II type of enrolled patients has to be analyzed and taken into consideration in the interpretation of the data.
Early phase trials in RRMS aiming to assess safety and preliminary efficacy should include 
Conclusion
In summary, induction of immune tolerance in pathogenic T cells remains the only therapeutic strategy with the potential to treat autoimmune disease at its roots and thus being able to cure the disease. Despite the fact that several attempts in MS patients failed due to either side effects or lack of efficacy, novel strategies hold the promise that the goal of immune tolerance can still be reached. Several key point have to be considered in future clinical development of such approaches. First, strategies should aim to induce tolerance to several myelin epitopes simultaneously. Second, future clinical trials should focus on patients early in the disease, when autoreactive inflammation is predominant and epitope spreading still limited. Third, robust immunological assays should be developed to follow antigenspecific T cells in treated patients, measure immunological outcome parameters, and provide information on the mechanism of action of therapy and immune tolerance. 
